Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes
- PMID: 15539641
- DOI: 10.1124/mol.104.003376
Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes
Abstract
Adenosine A(2A) and dopamine D(2) receptors have been shown previously to form heteromeric complexes and interact at the level of agonist binding, G protein coupling, and trafficking. Because dopamine D(2) and D(3) receptors show a high degree of sequence homology, A(2A) and D(3) receptors may also interact in a similar manner. The present studies with confocal microscopy showed that A(2A)-yellow fluorescent protein (YFP) and D(3)-green fluorescent protein 2 (GFP2) receptors colocalize in the plasma membrane. Furthermore, fluorescence resonance energy transfer (FRET) analysis demonstrated that A(2A)-YFP and D(3)-GFP2 receptors give a positive FRET efficiency and are thereby likely to exist as heteromeric A(2A)/D(3) receptor complexes. Saturation experiments with [(3)H]dopamine demonstrated that the A(2A) receptor agonist 4-[2-[[6-amino-9(N-ethyl-beta-d-ribofuranuronaminoamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid (CGS-21680) reduced the affinity of the high-affinity agonist binding state of the D(3) receptor for [(3)H]dopamine. The A(2A) and D(2A) receptors seem to interact also at the level of G protein coupling, because the adenosine A(2A) receptor agonist CGS-21680 fully counteracted the D(3) receptor-mediated inhibition of a forskolin-mediated increase in cAMP levels. Taken together, when coexpressed in the same neuron, A(2A) and D(3) receptors seem to form A(2A)/D(3) heteromeric receptor complexes in which A(2A) receptors antagonistically modulate both the affinity and the signaling of the D(3) receptors. D(3) receptor is one of the therapeutic _targets for treatment of schizophrenia, and therefore, the A(2A)/D(3) receptor interactions could provide an alternative antischizophrenic treatment.
Similar articles
-
Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells.Mol Pharmacol. 2008 Sep;74(3):544-51. doi: 10.1124/mol.108.047472. Epub 2008 Jun 4. Mol Pharmacol. 2008. PMID: 18524886
-
Cocaine produces D2R-mediated conformational changes in the adenosine A(2A)R-dopamine D2R heteromer.Biochem Biophys Res Commun. 2010 Apr 16;394(4):988-92. doi: 10.1016/j.bbrc.2010.03.104. Epub 2010 Mar 20. Biochem Biophys Res Commun. 2010. PMID: 20307491
-
On the existence of a possible A2A-D2-β-Arrestin2 complex: A2A agonist modulation of D2 agonist-induced β-arrestin2 recruitment.J Mol Biol. 2011 Mar 11;406(5):687-99. doi: 10.1016/j.jmb.2011.01.022. Epub 2011 Jan 20. J Mol Biol. 2011. PMID: 21256133
-
Adenosine A2A-dopamine D2 receptor-receptor heteromers. _targets for neuro-psychiatric disorders.Parkinsonism Relat Disord. 2004 Jul;10(5):265-71. doi: 10.1016/j.parkreldis.2004.02.014. Parkinsonism Relat Disord. 2004. PMID: 15196504 Review.
-
Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.Mov Disord. 2007 Oct 31;22(14):1990-2017. doi: 10.1002/mds.21440. Mov Disord. 2007. PMID: 17618524 Review.
Cited by
-
Adenosine A2a receptors form distinct oligomers in protein detergent complexes.FEBS Lett. 2016 Sep;590(18):3295-306. doi: 10.1002/1873-3468.12367. Epub 2016 Sep 2. FEBS Lett. 2016. PMID: 27543907 Free PMC article.
-
Class A and C GPCR Dimers in Neurodegenerative Diseases.Curr Neuropharmacol. 2022;20(11):2081-2141. doi: 10.2174/1570159X20666220327221830. Curr Neuropharmacol. 2022. PMID: 35339177 Free PMC article. Review.
-
Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia.Cells. 2020 Apr 27;9(5):1077. doi: 10.3390/cells9051077. Cells. 2020. PMID: 32349279 Free PMC article. Review.
-
Dopamine and renal function and blood pressure regulation.Compr Physiol. 2011 Jul;1(3):1075-117. doi: 10.1002/cphy.c100032. Compr Physiol. 2011. PMID: 23733636 Free PMC article. Review.
-
Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment.J Neural Transm (Vienna). 2019 Apr;126(4):455-471. doi: 10.1007/s00702-019-01969-2. Epub 2019 Jan 14. J Neural Transm (Vienna). 2019. PMID: 30637481 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources